Last updated: February 13, 2026
What Is the Drug Identified by NDC 81520-0250?
NDC 81520-0250 corresponds to Ubrogepant 50 mg, marketed under the brand name Ubrelvy. Ubrogepant is a first-in-class calcitonin gene-related peptide (CGRP) receptor antagonist approved by the FDA in October 2019 for the acute treatment of migraine in adults.
Market Size and Growth Dynamics
Current Market Landscape
- Migraine affects approximately 39 million Americans and 1 billion globally.
- The acute migraine treatment market was valued at approximately $1.2 billion in 2022 (Source: IQVIA).
- Ubrogepant accounts for a significant segment of this market, with estimated sales of $145 million in 2022 in the U.S.
Key Competitors
- Rimegepant (Nurtec ODT): Introduced in 2019, similar indication.
- Erenumab (Aimovig), Fremanezumab (Ajovy), and Eptinezumab (Vyepti): Monoclonal antibodies for prevention, not acute treatment but influence market size.
- Prior to Ubrogepant, triptans (sumatriptan, rizatriptan) dominated the acute migraine treatment market.
Market Drivers
- Growing prevalence of migraine.
- Increased awareness of CGRP-based therapies.
- Expanded insurance coverage and patient access.
Price Trends and Projections
Current Pricing
- Wholesale Acquisition Cost (WAC): Estimated at $65 - $65.50 per tablet.
- Average Selling Price (ASP): Approximately $70 per tablet.
- Insurers often negotiate rebates, reducing actual transaction prices.
Pricing Compared to Competitors
| Drug |
Dosage |
WAC per Tablet |
Marketed Since |
Price Relative to Ubrelvy |
| Ubrelvy (Ubrogepant) |
50 mg, 100 mg |
~$65 |
2019 |
Baseline |
| Nurtec ODT (Rimegepant) |
75 mg |
~$68 |
2019 |
Slightly higher |
| Sumatriptan (Imitrex) |
100 mg |
~$40 |
1991 |
Lower |
Future Price and Market Projections
The acute migraine market is expected to grow at a Compound Annual Growth Rate (CAGR) of 4-6% through 2027, driven by increased awareness and expansion of indications.
- 2025 Projection: Ubrogepant's annual sales could reach $380-$450 million in the U.S.
- Price Expectations: No significant downward pressure expected; prices are likely to remain stable or increase modestly due to inflation and formulation improvements.
International markets are expanding, especially in Europe and Asia, where regulatory approvals are ongoing. Prices outside the U.S. generally range from $50–$80 per tablet.
Market Access and Reimbursement
- Ubrogepant is covered by most commercial insurers and Medicare Part D plans.
- Reimbursement varies with negotiated rebates, affecting net sales.
- As new data on efficacy and safety emerge, pricing could adjust, especially if formulary placements improve or decline.
Risks and Opportunities
Risks:
- Patent expiration projected around 2029.
- Market entry of biosimilars or generic competitors.
- Price pressures due to competitive launches or insurance negotiations.
Opportunities:
- Extension of indications to preventive treatment.
- Development of combination therapies.
- International expansion beyond initial launch regions.
Key Takeaways
- NDC 81520-0250 (Ubrogepant 50 mg) has a market size of roughly $145 million in the U.S. (2022).
- Current wholesale price per tablet is approximately $65–$70.
- The global market for acute migraine treatment will grow at 4-6% CAGR through 2027.
- Sales projections suggest revenues could approach $380-$450 million by 2025 in the U.S.
- Pricing stability is expected, with slight increases aligning with inflation and market dynamics.
- Patent expiration around 2029 presents potential future generic entry risks.
FAQs
1. Is Ubrogepant likely to see price increases?
Yes, prices might increase modestly due to inflation, formulary positioning, or formulation improvements. Significant hikes are improbable absent regulatory or market changes.
2. How does Ubrogepant compare in price with alternative acute migraine treatments?
It is priced higher than triptans (~$40 per tablet) but remains competitive relative to rimegepant (~$68). Monoclonal antibodies for prevention are priced much higher but are used differently.
3. What factors could influence Ubrogepant’s market share?
Regulatory approvals for new indications, competitive entries, payer coverage changes, and real-world efficacy data.
4. What is the patent profile for Ubrogepant?
Patent protection extends into 2029, after which generics could enter. Patent challenges or filings may alter this timeline.
5. What markets outside the U.S. are promising for Ubrogepant?
Europe and Asia are expanding markets; regulatory approvals are in progress, with pricing generally aligned with U.S. levels.
Sources
- IQVIA, 2022.
- FDA, 2019.
- EvaluatePharma, 2022.
- SSRHealth, 2022.
- U.S. Patent and Trademark Office, 2022.
